Elmiron

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
15-07-2022
产品特点 产品特点 (SPC)
15-07-2022
公众评估报告 公众评估报告 (PAR)
20-06-2017

有效成分:

pentosan polysulfate sodium

可用日期:

bene-Arzneimittel GmbH

ATC代码:

G04BX15

INN(国际名称):

pentosan polysulfate sodium

治疗组:

Urologicals

治疗领域:

Cystitis, Interstitial

疗效迹象:

Elmiron is indicated for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition.,

產品總結:

Revision: 14

授权状态:

Authorised

授权日期:

2017-06-02

资料单张

                                22
B. PACKAGE LEAFLET
23
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ELMIRON
100 MG CAPSULES, HARD
pentosan polysulfate sodium
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What elmiron is and what it is used for
2.
What you need to know before you take elmiron
3.
How to take elmiron
4.
Possible side effects
5.
How to store elmiron
6.
Contents of the pack and other information
1.
WHAT ELMIRON IS AND WHAT IT IS USED FOR
elmiron is a medicine that contains the active substance pentosan
polysulfate sodium. After taking the
medicine, it passes into the urine and attaches to the lining of the
bladder, helping to form a protective
layer.
elmiron is used in adults to treat
BLADDER PAIN SYNDROME
characterised by many tiny bleeds or
distinctive lesions on the bladder wall and moderate to severe pain
and a frequent urge to urinate.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ELMIRON
DO NOT TAKE ELMIRON IF YOU ARE
•
ALLERGIC
to pentosan polysulfate sodium or any of the other ingredients of this
medicine (listed
in section 6)
•
BLEEDING
(other than menstrual bleeding)
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before taking elmiron if you have:
•
to undergo surgery
•
a blood clotting disorder or increased risks of bleeding, such as
using a medicine that inhibits
blood clotting
•
ever had a reduced number of blood platelets caused by the medicine
called heparin
•
reduced liver or kidney function
Rare cases of retinal disorders (pigmentary maculopathy) have been
reported with us
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
elmiron 100 mg capsules, hard
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains 100 mg of pentosan polysulfate sodium.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Capsule, hard.
White opaque capsules size 2.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
elmiron is indicated for the treatment of bladder pain syndrome
characterized by either glomerulations
or Hunner’s lesions in adults with moderate to severe pain, urgency
and frequency of micturition (see
section 4.4).
_ _
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults _
The recommended dose of pentosan polysulfate sodium is 300 mg/day
taken as one 100 mg capsule
orally three times daily.
Response to treatment with pentosan polysulfate sodium should be
reassessed every 6 months. In case
no improvement is reached 6 months after treatment initiation,
treatment with pentosan polysulfate
sodium should be stopped. In responders pentosan polysulfate sodium
treatment should be continued
chronically as long as the response is maintained.
_Special populations _
Pentosan polysulfate sodium has not been specifically studied in
special patient populations like
elderly or patients with renal or hepatic impairment (see section
4.4). No dose adjustment is
recommended for these patients.
_Paediatric population _
The safety and efficacy of pentosan polysulfate sodium in children and
adolescent below 18 years has
not been established.
No data are available.
Method of administration
The capsules should be taken with water at least 1 hour before meals
or 2 hours after meals.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.
3
Due to the weak anticoagulant effect of pentosan polysulfate sodium,
elmiron must not be used in
patients who actively bleed. Menstruation is no contraindication.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Bladder pain syndrome is a diagnosis of exclusion
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 15-07-2022
产品特点 产品特点 保加利亚文 15-07-2022
公众评估报告 公众评估报告 保加利亚文 20-06-2017
资料单张 资料单张 西班牙文 15-07-2022
产品特点 产品特点 西班牙文 15-07-2022
公众评估报告 公众评估报告 西班牙文 20-06-2017
资料单张 资料单张 捷克文 15-07-2022
产品特点 产品特点 捷克文 15-07-2022
公众评估报告 公众评估报告 捷克文 20-06-2017
资料单张 资料单张 丹麦文 15-07-2022
产品特点 产品特点 丹麦文 15-07-2022
公众评估报告 公众评估报告 丹麦文 20-06-2017
资料单张 资料单张 德文 15-07-2022
产品特点 产品特点 德文 15-07-2022
公众评估报告 公众评估报告 德文 20-06-2017
资料单张 资料单张 爱沙尼亚文 15-07-2022
产品特点 产品特点 爱沙尼亚文 15-07-2022
公众评估报告 公众评估报告 爱沙尼亚文 20-06-2017
资料单张 资料单张 希腊文 15-07-2022
产品特点 产品特点 希腊文 15-07-2022
公众评估报告 公众评估报告 希腊文 20-06-2017
资料单张 资料单张 法文 15-07-2022
产品特点 产品特点 法文 15-07-2022
公众评估报告 公众评估报告 法文 20-06-2017
资料单张 资料单张 意大利文 15-07-2022
产品特点 产品特点 意大利文 15-07-2022
公众评估报告 公众评估报告 意大利文 20-06-2017
资料单张 资料单张 拉脱维亚文 15-07-2022
产品特点 产品特点 拉脱维亚文 15-07-2022
公众评估报告 公众评估报告 拉脱维亚文 20-06-2017
资料单张 资料单张 立陶宛文 15-07-2022
产品特点 产品特点 立陶宛文 15-07-2022
公众评估报告 公众评估报告 立陶宛文 20-06-2017
资料单张 资料单张 匈牙利文 15-07-2022
产品特点 产品特点 匈牙利文 15-07-2022
公众评估报告 公众评估报告 匈牙利文 20-06-2017
资料单张 资料单张 马耳他文 15-07-2022
产品特点 产品特点 马耳他文 15-07-2022
公众评估报告 公众评估报告 马耳他文 20-06-2017
资料单张 资料单张 荷兰文 15-07-2022
产品特点 产品特点 荷兰文 15-07-2022
公众评估报告 公众评估报告 荷兰文 20-06-2017
资料单张 资料单张 波兰文 15-07-2022
产品特点 产品特点 波兰文 15-07-2022
公众评估报告 公众评估报告 波兰文 20-06-2017
资料单张 资料单张 葡萄牙文 15-07-2022
产品特点 产品特点 葡萄牙文 15-07-2022
公众评估报告 公众评估报告 葡萄牙文 20-06-2017
资料单张 资料单张 罗马尼亚文 15-07-2022
产品特点 产品特点 罗马尼亚文 15-07-2022
公众评估报告 公众评估报告 罗马尼亚文 20-06-2017
资料单张 资料单张 斯洛伐克文 15-07-2022
产品特点 产品特点 斯洛伐克文 15-07-2022
公众评估报告 公众评估报告 斯洛伐克文 20-06-2017
资料单张 资料单张 斯洛文尼亚文 15-07-2022
产品特点 产品特点 斯洛文尼亚文 15-07-2022
公众评估报告 公众评估报告 斯洛文尼亚文 20-06-2017
资料单张 资料单张 芬兰文 15-07-2022
产品特点 产品特点 芬兰文 15-07-2022
公众评估报告 公众评估报告 芬兰文 20-06-2017
资料单张 资料单张 瑞典文 15-07-2022
产品特点 产品特点 瑞典文 15-07-2022
公众评估报告 公众评估报告 瑞典文 20-06-2017
资料单张 资料单张 挪威文 15-07-2022
产品特点 产品特点 挪威文 15-07-2022
资料单张 资料单张 冰岛文 15-07-2022
产品特点 产品特点 冰岛文 15-07-2022
资料单张 资料单张 克罗地亚文 15-07-2022
产品特点 产品特点 克罗地亚文 15-07-2022
公众评估报告 公众评估报告 克罗地亚文 20-06-2017

搜索与此产品相关的警报

查看文件历史